Metformin: how it works, why the longevity interest, and what it depletes

Sixty years of use, one of the best-characterised safety profiles in medicine, and a second life as a longevity candidate on evidence that is thinner than its reputation suggests. What it does, and the two monitoring items that are genuinely non-optional.

What it does, and where it does it

Established clinical use Metformin's dominant effect is on the liver: it suppresses hepatic gluconeogenesis, which is the process that keeps blood glucose up between meals and which runs inappropriately high in type 2 diabetes. It does this largely without stimulating insulin secretion, which is why it does not cause hypoglycaemia on its own. Secondary effects include improved peripheral insulin sensitivity and altered gut glucose handling — the gut contribution is larger than was appreciated for decades and is part of why the extended-release formulation works despite lower peak concentrations.

The mechanism at the molecular level is usually given as AMPK activation, and that is part of it, but the fuller account is inhibition of mitochondrial complex I, which raises the cell's AMP-to-ATP ratio and activates AMPK as a consequence. AMPK-independent effects on hepatic glucose production have also been demonstrated. The short version — "it activates AMPK" — is the one that circulates, and it is a simplification of an incompletely settled question.

Its half-life is short: the app models six hours, with the peak about two and a half hours after an immediate-release dose. That is why it is taken with meals two or three times a day in the immediate-release form, and why the extended-release version exists at all.

The longevity case, stated accurately

Off-label or community practice The interest comes from observational work: cohorts of people with diabetes taking metformin appeared to have mortality closer to non-diabetic controls than to diabetic controls on other treatments. That is a striking observation and it is also the kind of comparison most vulnerable to confounding, because metformin is prescribed to people at an earlier and healthier stage of disease than the drugs it was compared against.

Animal-only or theoretical The TAME trial was designed to test the question directly in people without diabetes, with agreement from the FDA on a composite ageing-related endpoint — a regulatory first that is often mis-reported as approval of an indication. Its funding history has been difficult and it has not reported. Until it does, the honest summary is that metformin's longevity case rests on animal data, mechanism and confounded observational comparisons, which is a reasonable basis for interest and not a basis for confidence.

Animal-only or theoretical The exercise question cuts the other way and deserves mention. Several controlled trials have found that metformin blunts some of the adaptations to resistance and aerobic training in older adults; others have not. The finding is unresolved rather than established, and it is directly relevant to anyone taking it alongside a training programme.

The two things that are not optional

Vitamin B12 depletion is real, dose-related and cumulative over years, and it can present as a peripheral neuropathy that is easy to attribute to diabetes itself. Established clinical use Periodic B12 measurement is standard in the guidance for long-term use, and the app records it on the monitoring panel for exactly this reason. It is the single most commonly skipped item on a metformin panel.

Renal function is the other. Metformin is cleared by the kidney and does not undergo hepatic metabolism, so impaired clearance raises the level. Lactic acidosis — the serious adverse effect — is rare, and it is overwhelmingly associated with significant renal impairment, acute illness or contrast procedures rather than with ordinary use. This is why eGFR appears on the panel and why prescribing information carries thresholds below which it is reduced or stopped.

Gastrointestinal intolerance is the common reason people stop, and it is substantially formulation-dependent: the extended-release form is better tolerated at the same daily amount. Any of this that you are experiencing belongs with the clinician who prescribes it — the dose, the formulation and the decision to continue are all theirs to make with your kidney function in front of them.

How long one dose lasts

Try other intervals on the half-life and steady-state calculator, which runs the same function against whatever cadence you type.

The dosing rows the app records

Established clinical use Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for Metformin, verbatim. The analytes in it that have a page here are linked; those pages cover what each one measures, which assay produced it and how to read a trend.

• Hematocrit on testosterone therapy
• HbA1c and fasting glucose

Drawbacks and risks the app records

From the app's own entry, and unusually well-founded for a compound page: metformin has been prescribed at scale for six decades, so its drawback list is drawn from evidence rather than from case reports.

• GI side effects (nausea, diarrhea) — especially initially
• Reduces Vitamin B12 absorption — supplement required
• May blunt exercise adaptations (controversial — conflicting studies)
• Lactic acidosis risk (rare — primarily with renal impairment)
• Not FDA approved for longevity use
• Requires physician prescription

Interaction rules that name Metformin

From the app’s interaction data, filtered so no rule naming a compound this site does not publish appears. Not exhaustive, and not a safety clearance: a combination that is not listed is one nobody has documented here, which is not the same as one that is fine. The combination checker has the rest.

Questions people actually ask

Does metformin work in people without diabetes?

It lowers hepatic glucose output regardless, and it produces modest improvements in insulin sensitivity in people with insulin resistance short of diabetes. Whether that translates into the outcomes the longevity interest is about is exactly the open question TAME was designed to answer. It requires a prescription and the decision is a clinician's.

Immediate-release or extended-release?

The extended-release form produces lower peak concentrations and is consistently better tolerated for gastrointestinal effects at the same daily amount, which is why it is usually preferred when tolerance is the limiting factor. Both are on the app's dosing rows above. Which one, and how much, is a prescribing decision.

How long until anything shows up on bloodwork?

Fasting glucose responds within days to weeks. HbA1c reflects roughly the preceding three months of glycaemia, so a panel drawn earlier than about eight weeks after a change is reporting mostly the old state. The HbA1c page covers why the two markers disagree and what that disagreement means.

Should B12 be supplemented preventively?

Preventive supplementation is widely practised and is what the app's own protocol note describes. Measuring rather than assuming is the more informative version, because a normal B12 with a rising methylmalonic acid is the early picture and a supplement taken blindly hides it. Either way this is a conversation with the prescriber.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.